Lenalidomide and rituximab for relapsed/refractory follicular lymphoma: a systematic review and meta-analysis
In brief
Lenalidomide-rituximab produces responses in 76% of relapsed follicular lymphoma
Across 24 treatment arms involving 2,245 patients, lenalidomide with rituximab or another anti-CD20 drug produced an overall response in about 76%; about 40% had a complete response. Adding a third drug did not raise overall response but was linked to more complete responses and longer progression-free survival, alongside more severe toxicity, so patient selection and monitoring remain important.
- Journal
- Blood cancer journal (Q1)
- Published
- 21 August 2026
- Study design
- Systematic review of cohort studies
- Evidence level
- Level 2, Moderate (CEBM 2a)
- Authors
- Sarah Matarasso Greenfeld, Rakan Okde, Mark Sorin, Olivia Benguigui, Joseph Tuscano, Maria Sannikova, et al.
- PMID
- 43039893
- DOI
- 10.1038/s41408-026-01608-6
Why clinicians should know about it
- Picked for Hematology (paper of the day, 19 November 2026): Systematic efficacy and toxicity review of relapsed follicular lymphoma therapy
Abstract
Lenalidomide (len) and rituximab (R2) is standard second-line therapy for follicular lymphoma (FL), and the backbone and comparator for several new therapies. This systematic review and meta-analysis of R2 or len-anti-CD20 monoclonal antibodies aims to clarify efficacy across trials, and to evaluate the benefit of triplet therapies including R2. Across 24 treatment arms involving 2245 patients, 63% received R2 or len-anti-CD20 and 37% received it with an additional agent. For R2/len-anti-CD20, the overall response rate (ORR) was 75.9% (95% CI 72.1-79.3, p = 0.0092; I2 = 53.5%), and complete response rates (CR), 39.6% (95% CI 32.4-47.3, p < 0.0001, I2 = 73.2%). ORRs were similar whether studies included or excluded rituximab-refractory, but CR appeared lower (28.6% vs. 42.9%). The number of prior lines of therapy did not affect response. Adding a third agent to R2 or len-anti-CD20 resulted in similar ORRs but significantly higher CR and 1- and 2-year progression-free survival appeared longer than that seen with R2. However, triplet regimens were associated with increased grade ≥3 toxicity. These findings reinforce the role of R2 in R/R FL in the modern treatment era. R2 at first relapse is effective across rituximab sensitivity profiles. Triplet combinations built on the R2 backbone improve efficacy but require careful patient selection and monitoring due to higher toxicity risks.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.